SGLT2i预防经皮冠状动脉介入术后支架内再狭窄的研究进展

doi:10.3969/j.issn.1006-5725.2024.08.027

Abstract

Abstract:

In-stent restenosis is one of the main causes of postoperative complications after percutaneous coronary intervention and a challenge in the field of intervention.Sodium-glucose cotransporter 2 inhibitors （SGLT2i）are new oral hypoglycemic agents used in the treatment of diabetes in recent years. In addition to lowering bloodglucose， they also have the effects of lowering blood pressure， improving blood lipids， and reducing weight， thereby protecting cardiovascular function. Recent studies have shown that SGLT2i can reduced the occurrence of in-stent restenosis and significantly improved the prognosis of patients with coronary heart disease receiving interventional therapy.This article reviews the clinical studies and mechanisms of SGLT2i in the prevention of restenosis after percutaneous coronary intervention， providing new ideas for improving the clinical prognosis of patients with coronary heart disease.

Key words: sodium-glucose cotransporter 2 inhibitor, in-stent restenosis, coronary heart disease

CLC Number:

R541.4

Qing ZHANG,Tudi LI,Rong CHEN,Zhihuan. ZENG. Research progress on sodium⁃glucose cotransporter 2 inhibitors for in⁃stent restenosis after percutaneous coronary intervention[J]. The Journal of Practical Medicine, 2024, 40(8): 1175-1180.

References 56

1	《中国心血管健康与疾病报告2022》编写组. 《中国心血管健康与疾病报告2022》要点解读［J］. 中国心血管杂志， 2023， 28（4）： 297-312.
2	杨尚铭，李首才，耿超强，等. 经皮冠状动脉介入术后支架内再狭窄的研究进展［J］. 中西医结合心脑血管病杂志， 2023， 21（20）： 3754-3760. doi:10.12102/j.issn.1672-1349.2023.20.013 doi: 10.12102/j.issn.1672-1349.2023.20.013
3	ERDOGAN E， BAJAJ R， LANSKY A， et al. Intravascular Imaging for Guiding In-Stent Restenosis and Stent Thrombosis Therapy ［J］. J Am Heart Assoc， 2022， 11（22）： e026492. doi:10.1161/jaha.122.026492 doi: 10.1161/jaha.122.026492
4	CONNELLY K， CAI S. Softening the Stiff Heart： SGLT2 Inhibition and Diastolic Function ［J］. JACC Cardiovasc Imaging， 2021， 14（2）： 408-410. doi:10.1016/j.jcmg.2020.08.020 doi: 10.1016/j.jcmg.2020.08.020
5	PACKER M. SGLT2 inhibitors： role in protective reprogramming of cardiac nutrient transport and metabolism ［J］. Nat Rev Cardiol， 2023， 20（7）： 443-462. doi:10.1038/s41569-022-00824-4 doi: 10.1038/s41569-022-00824-4
6	MCMURRAY J J V， SOLOMON S D， INZUCCHI S E， et al. Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction ［J］. N Engl J Med， 2019， 381（21）： 1995-2008.
7	YOUSSEF M E， YAHYA G， POPOVICIU M S， et al. Unlocking the Full Potential of SGLT2 Inhibitors： Expanding Applications beyond Glycemic Control ［J］. Int J Mol Sci， 2023， 24（7）： 6039. doi:10.3390/ijms24076039 doi: 10.3390/ijms24076039
8	MCDONAGH T A， METRA M， ADAMO M， et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure ［J］. Eur Heart J， 2021， 42（36）： 3599-3726.
9	MCDONAGH T A， METRA M， ADAMO M， et al. 2023 Focused Update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure ［J］. Eur Heart J， 2023， 44（37）： 3627-3639.
10	ELSAYED N A， ALEPPO G， ARODA V R， et al. 10. Cardiovascular Disease and Risk Management： Standards of Care in Diabetes-2023 ［J］. Diabetes Care， 2023， 46（）： S158-S190. doi:10.2337/dc23-er04 doi: 10.2337/dc23-er04
11	MARFELLA R， SARDU C， D'ONOFRIO N， et al. SGLT-2 inhibitors and in-stent restenosis-related events after acute myocardial infarction： an observational study in patients with type 2 diabetes ［J］. BMC Med， 2023， 21（1）： 71. doi:10.1186/s12916-023-02781-2 doi: 10.1186/s12916-023-02781-2
12	江耀辉，王喆，郑汝杰，等. 达格列净对2型糖尿病药物洗脱支架植入后临床结局的影响［J］. 临床心血管病杂志， 2021， 37（11）： 1014-1019.
13	任园园，洪晋，黄玉起，等. 达格列净对2型糖尿病合并急性冠脉综合征患者PCI术后心功能和支架内再狭窄情况的影响［J］. 河南医学研究， 2021， 30（17）： 3117-3122. doi:10.3969/j.issn.1004-437X.2021.17.012 doi: 10.3969/j.issn.1004-437X.2021.17.012
14	刘家荣，郑小鹏. 卡格列净对冠心病合并糖尿病患者冠脉药物洗脱支架内再狭窄的影响［J］. 心血管病防治知识， 2022， 12（20）： 15-18. doi:10.3969/j.issn.1672-3015(x).2022.20.004 doi: 10.3969/j.issn.1672-3015(x).2022.20.004
15	张海良，张学丹. 老年急性STEMI患者PCI术后支架内再狭窄的危险因素Logistic回归分析［J］. 临床医学研究与实践， 2019， 4（6）： 86-87.
16	张飞飞，谢悦陶，刘立天，等. 经皮冠状动脉药物洗脱支架术后再狭窄影响因素分析［J］. 实用医学杂志， 2020， 36（14）： 1946-1951.
17	SABERZADEH-ARDESTANI B， KARAMZADEH R， BASIRI M， et al. Type 1 Diabetes Mellitus： Cellular and Molecular Pathophysiology at A Glance ［J］. Cell J， 2018， 20（3）： 294-301.
18	SPADACCIO C， PATTI G， DE MARCO F， et al. Usefulness of preprocedural levels of advanced glycation end products to predict restenosis in patients with controlled diabetes mellitus undergoing drug-eluting stent implantation for stable angina pectoris （from the Prospective ARMYDA-AGEs Study）［J］. Am J Cardiol， 2013， 112（1）： 21-26. doi:10.1016/j.amjcard.2013.02.046 doi: 10.1016/j.amjcard.2013.02.046
19	LEXIS C P， RAHEL B M， MEEDER J G， et al. The role of glucose lowering agents on restenosis after percutaneous coronary intervention in patients with diabetes mellitus ［J］. Cardiovasc Diabetol， 2009， 8： 41. doi:10.1186/1475-2840-8-41 doi: 10.1186/1475-2840-8-41
20	YAO D， WANG S， WANG M， et al. Renoprotection of dapagliflozin in human renal proximal tubular cells via the inhibition of the high mobility group box 1‑receptor for advanced glycation end products‑nuclear factor‑kappaB signaling pathway ［J］. Mol Med Rep， 2018， 18（4）： 3625-3630.
21	SUN H， CHEN J， HUA Y， et al. New insights into the role of empagliflozin on diabetic renal tubular lipid accumulation ［J］. Diabetol Metab Syndr， 2022， 14（1）： 121. doi:10.1186/s13098-022-00886-x doi: 10.1186/s13098-022-00886-x
22	JOUBERT M， JAGU B， MONTAIGNE D， et al. The Sodium-Glucose Cotransporter 2 Inhibitor Dapagliflozin Prevents Cardiomyopathy in a Diabetic Lipodystrophic Mouse Model ［J］. Diabetes， 2017， 66（4）： 1030-1040. doi:10.2337/db16-0733 doi: 10.2337/db16-0733
23	DI PINO A， DEFRONZO R A. Insulin Resistance and Atherosclerosis： Implications for Insulin-Sensitizing Agents ［J］. Endocr Rev， 2019， 40（6）： 1447-1467. doi:10.1210/er.2018-00141 doi: 10.1210/er.2018-00141
24	楼善杰，黄诚意，刘旭. 冠心病非糖尿病患者胰岛素抵抗与支架内再狭窄相关性［J］. 中华实用诊断与治疗杂志， 2015， 29（10）： 1016-1018.
25	ZHAO L P， XU W T， WANG L， et al. Influence of insulin resistance on in-stent restenosis in patients undergoing coronary drug-eluting stent implantation after long-term angiographic follow-up ［J］. Coron Artery Dis， 2015， 26（1）： 5-10. doi:10.1097/mca.0000000000000170 doi: 10.1097/mca.0000000000000170
26	SASSO F C， PAFUNDI P C， MARFELLA R， et al. Adiponectin and insulin resistance are related to restenosis and overall new PCI in subjects with normal glucose tolerance： the prospective AIRE Study ［J］. Cardiovasc Diabetol， 2019， 18（1）： 24. doi:10.1186/s12933-019-0826-0 doi: 10.1186/s12933-019-0826-0
27	张越，王丽宏. 钠-葡萄糖共转运蛋白2抑制剂在改善胰岛素抵抗和胰岛β细胞功能方面的研究进展［J］. 临床内科杂志， 2023， 40（3）： 213-215. doi:10.3969/j.issn.1001-9057.2023.03.022 doi: 10.3969/j.issn.1001-9057.2023.03.022
28	NISHITANI S， FUKUHARA A， SHIN J， et al. Metabolomic and microarray analyses of adipose tissue of dapagliflozin-treated mice， and effects of 3-hydroxybutyrate on induction of adiponectin in adipocytes ［J］. Sci Rep， 2018， 8（1）： 8805. doi:10.1038/s41598-018-27181-y doi: 10.1038/s41598-018-27181-y
29	BONNET F， SCHEEN A J. Effects of SGLT2 inhibitors on systemic and tissue low-grade inflammation： The potential contribution to diabetes complications and cardiovascular disease ［J］. Diabetes Metab， 2018， 44（6）： 457-464. doi:10.1016/j.diabet.2018.09.005 doi: 10.1016/j.diabet.2018.09.005
30	YARIBEYGI H， SIMENTAL-MENDIA L E， BARRETO G E， et al. Metabolic effects of antidiabetic drugs on adipocytes and adipokine expression ［J］. J Cell Physiol， 2019， 234（10）： 16987-16997. doi:10.1002/jcp.28420 doi: 10.1002/jcp.28420
31	CASON C A， KUNTZ T M， CHEN E B， et al. Microbiota composition modulates inflammation and neointimal hyperplasia after arterial angioplasty ［J］. J Vasc Surg， 2020， 71（4）： 1378-1389.e3. doi:10.1016/j.jvs.2019.06.208 doi: 10.1016/j.jvs.2019.06.208
32	NICULESCU R， RUSSU E， ARBANASI E M， et al. Carotid Plaque Features and Inflammatory Biomarkers as Predictors of Restenosis and Mortality Following Carotid Endarterectomy ［J］. Int J Environ Res Public Health， 2022， 19（21）： 13934. doi:10.3390/ijerph192113934 doi: 10.3390/ijerph192113934
33	谈昀，马兰香，张树苗，等. 急性心肌梗死PCI术后支架内再狭窄患者的CRP、Hcy、CysC、NT-proBNP、LDL-C变化及临床意义［J］. 海南医学， 2022， 33（14）： 1799-1802. doi:10.3969/j.issn.1003-6350.2022.14.009 doi: 10.3969/j.issn.1003-6350.2022.14.009
34	王大鹏，冯玉婧，裴建军，等. 药物涂层球囊扩张成形术对颈动脉支架内再狭窄患者术后再狭窄及炎症因子水平的影响［J］. 中国医刊， 2023， 58（4）： 409-412. doi:10.3969/j.issn.1008-1070.2023.04.017 doi: 10.3969/j.issn.1008-1070.2023.04.017
35	GASPARI T， SPIZZO I， LIU H， et al. Dapagliflozin attenuates human vascular endothelial cell activation and induces vasorelaxation： A potential mechanism for inhibition of atherogenesis ［J］. Diab Vasc Dis Res， 2018， 15（1）： 64-73. doi:10.1177/1479164117733626 doi: 10.1177/1479164117733626
36	ZHENG D， LIU J， PIAO H， et al. ROS-triggered endothelial cell death mechanisms： Focus on pyroptosis， parthanatos， and ferroptosis ［J］. Front Immunol， 2022， 13： 1039241. doi:10.3389/fimmu.2022.1039241 doi: 10.3389/fimmu.2022.1039241
37	SOARES R N， RAMIREZ-PEREZ F I， CABRAL-AMADOR F J， et al. SGLT2 inhibition attenuates arterial dysfunction and decreases vascular F-actin content and expression of proteins associated with oxidative stress in aged mice ［J］. Geroscience， 2022， 44（3）： 1657-1675. doi:10.1007/s11357-022-00563-x doi: 10.1007/s11357-022-00563-x
38	王聪霞，贾珊. 冠状动脉支架内再狭窄发生机制的研究进展［J］. 西安交通大学学报（医学版）， 2018， 39（3）： 303-309.
39	BEHNAMMANESH G， DURANTE G L， KHANNA Y P， et al. Canagliflozin inhibits vascular smooth muscle cell proliferation and migration： Role of heme oxygenase-1 ［J］. Redox Biol， 2020， 32： 101527. doi:10.1016/j.redox.2020.101527 doi: 10.1016/j.redox.2020.101527
40	PEYTON K J， BEHNAMMANESH G， DURANTE G L， et al. Canagliflozin Inhibits Human Endothelial Cell Inflammation through the Induction of Heme Oxygenase-1 ［J］. Int J Mol Sci， 2022， 23（15）： 8777. doi:10.3390/ijms23158777 doi: 10.3390/ijms23158777
41	DUTZMANN J， BODE L M， KALIES K， et al. Empagliflozin prevents neointima formation by impairing smooth muscle cell proliferation and accelerating endothelial regeneration ［J］. Front Cardiovasc Med， 2022， 9： 956041. doi:10.3389/fcvm.2022.956041 doi: 10.3389/fcvm.2022.956041
42	KASAI A， SHINTANI N， ODA M， et al. Apelin is a novel angiogenic factor in retinal endothelial cells ［J］. Biochem Biophys Res Commun， 2004， 325（2）： 395-400. doi:10.1016/j.bbrc.2004.10.042 doi: 10.1016/j.bbrc.2004.10.042
43	ZHANG P， WANG A P， YANG H P， et al. Apelin-13 attenuates high glucose-induced calcification of MOVAS cells by regulating MAPKs and PI3K/AKT pathways and ROS-mediated signals ［J］. Biomed Pharmacother， 2020， 128： 110271. doi:10.1016/j.biopha.2020.110271 doi: 10.1016/j.biopha.2020.110271
44	廖耿. 支架内再狭窄的分子学机制研究进展［J］. 当代医学， 2013， 19（1）： 10-12. doi:10.3969/j.issn.1009-4393.2013.1.006 doi: 10.3969/j.issn.1009-4393.2013.1.006
45	DURANTE W， BEHNAMMANESH G， PEYTON K J. Effects of Sodium-Glucose Co-Transporter 2 Inhibitors on Vascular Cell Function and Arterial Remodeling ［J］. Int J Mol Sci， 2021， 22（16）： 8786. doi:10.3390/ijms22168786 doi: 10.3390/ijms22168786
46	AROOR A R， DAS N A， CARPENTER A J， et al. Glycemic control by the SGLT2 inhibitor empagliflozin decreases aortic stiffness， renal resistivity index and kidney injury ［J］. Cardiovasc Diabetol， 2018， 17（1）： 108. doi:10.1186/s12933-018-0750-8 doi: 10.1186/s12933-018-0750-8
47	SHIGIYAMA F， KUMASHIRO N， MIYAGI M， et al. Effectiveness of dapagliflozin on vascular endothelial function and glycemic control in patients with early-stage type 2 diabetes mellitus： DEFENCE study ［J］. Cardiovasc Diabetol， 2017， 16（1）： 84. doi:10.1186/s12933-017-0564-0 doi: 10.1186/s12933-017-0564-0
48	SAWADA T， UZU K， HASHIMOTO N， et al. Empagliflozin's Ameliorating Effect on Plasma Triglycerides： Association with Endothelial Function Recovery in Diabetic Patients with Coronary Artery Disease ［J］. J Atheroscler Thromb， 2020， 27（7）： 644-656. doi:10.5551/jat.50807 doi: 10.5551/jat.50807
49	IRACE C， CUTRUZZOLA A， PARISE M， et al. Effect of empagliflozin on brachial artery shear stress and endothelial function in subjects with type 2 diabetes： Results from an exploratory study ［J］. Diab Vasc Dis Res， 2020， 17（1）： 1479164119883540. doi:10.1177/1479164119883540 doi: 10.1177/1479164119883540
50	HASHIKATA T， IKUTOMI M， JIMBA T， et al. Empagliflozin attenuates neointimal hyperplasia after drug-eluting-stent implantation in patients with type 2 diabetes ［J］. Heart Vessels， 2020， 35（10）： 1378-1389. doi:10.1007/s00380-020-01621-0 doi: 10.1007/s00380-020-01621-0
51	LEE H F， CHAN Y H， CHUANG C， et al. Cardiovascular， renal， and lower limb outcomes in patients with type 2 diabetes after percutaneous coronary intervention and treated with sodium-glucose cotransporter 2 inhibitors vs. dipeptidyl peptidase-4 inhibitors ［J］. Eur Heart J Cardiovasc Pharmacother， 2023， 9（4）： 301-310. doi:10.1093/ehjcvp/pvad004 doi: 10.1093/ehjcvp/pvad004
52	王法斌，孙梦涵，赵强，等. 早期应用达格列净在急性心肌梗死急诊经皮冠状动脉介入术后患者中的有效性及安全性［J］. 实用医学杂志， 2023， 39（13）： 1688-1692. doi:10.3969/j.issn.1006-5725.2023.13.016 doi: 10.3969/j.issn.1006-5725.2023.13.016
53	盛雪，纪征，王兆翔，等. 达格列净联合诺欣妥对急性心肌梗死患者急诊介入治疗后心力衰竭的疗效［J］. 实用医学杂志， 2022， 38（11）： 1410-1414. doi:10.3969/j.issn.1006⁃5725.2022.11.020 doi: 10.3969/j.issn.1006?5725.2022.11.020
54	PAOLISSO P， BERGAMASCHI L， GRAGNANO F， et al. Outcomes in diabetic patients treated with SGLT2-Inhibitors with acute myocardial infarction undergoing PCI： The SGLT2-I AMI PROTECT Registry ［J］. Pharmacol Res， 2023， 187： 106597. doi:10.1016/j.phrs.2022.106597 doi: 10.1016/j.phrs.2022.106597
55	VON LEWINSKI D， KOLESNIK E， TRIPOLT N J， et al. Empagliflozin in acute myocardial infarction： the EMMY trial ［J］. Eur Heart J， 2022， 43（41）： 4421-4432. doi:10.1093/eurheartj/ehac494 doi: 10.1093/eurheartj/ehac494
56	TENTOLOURIS A， VLACHAKIS P， TZERAVINI E， et al. SGLT2 Inhibitors： A Review of Their Antidiabetic and Cardioprotective Effects ［J］. Int J Environ Res Public Health， 2019， 16（16）： 2965. doi:10.3390/ijerph16162965 doi: 10.3390/ijerph16162965

[1]	Fengxia QU,Yue XIN,Jingyuan LI,Xiao GUO,Changhong. LU. Evaluation of the efficacy of Internet+cardiac rehabilitation intervention in patients with hypertension and coronary heart disease [J]. The Journal of Practical Medicine, 2024, 40(19): 2778-2782.
[2]	Shuping GE,Wei CHEN,Xinxin JIA,Min GAO,Min HE,Cunyu. QIN. Effect of individual exercise training as the core cardiac rehabilitation program on the rehabilitation of patients with coronary heart disease after percutaneous coronary intervention [J]. The Journal of Practical Medicine, 2024, 40(18): 2607-2611.
[3]	Yalin YANG,Yang HU,Yunhong WEI,Jie DENG,Yu. WANG. Application value and progress of heart rate recovery in indication of cardiovascular diseases [J]. The Journal of Practical Medicine, 2024, 40(18): 2660-2664.
[4]	Sumeng WANG,Fangfang ZHANG,Liantao NIE,Kexin LUO,Shifeng. LI. The value of electrocardiographic parameters in assessment of severe coronary artery lesions [J]. The Journal of Practical Medicine, 2024, 40(17): 2465-2470.
[5]	Youming ZHANG,Junhui GONG,Hongtao ZHU. Relationship between serum CTRP12 level and in⁃stent restenosis in patients with acute myocardial infarction after percutaneous coronary intervention [J]. The Journal of Practical Medicine, 2024, 40(12): 1671-1676.
[6]	Yu WANG,Ying MIAO,Qiang LIN,Mao TIAN,Zhuang CHEN,Qin WAN. Association between TyG⁃WC and risk of coronary heart disease in middle⁃aged and elderly population： a prospective cohort study with 10⁃year follow⁃up [J]. The Journal of Practical Medicine, 2024, 40(12): 1731-1736.
[7]	Shan LONG,Xingde LIU,Tiantian LI,Yang ZOU,Haiyan ZHOU. Mechanisms and treatments of post⁃PCI anxiety and depression of patients with coronary heart disease： A review of literature [J]. The Journal of Practical Medicine, 2023, 39(21): 2850-2856.
[8]	Kun DU,Wentao CHEN,Xiaoling JU,Jie. WANG. Analysis of skin cholesterol determination combined with ECG treadmill exercise in diagnosis of coronary heart disease in patients with atypical chest pain [J]. The Journal of Practical Medicine, 2023, 39(20): 2671-2675.
[9]	FANG Ding⁃ feng, CHEN Haibo, XU Jiabin, MA Wei, YU Dongdong, ZHANG Meng, LI Haoliang, CHEN Zhenyu.. Research progress of intravascular ultrasound ⁃ guided percutaneous coronary intervention [J]. The Journal of Practical Medicine, 2022, 38(23): 3023-3026.
[10]	JIANG Xiaojie, LIU Liyun, FAN Yingli.. Feasibility and safety of low ⁃dose ticagrelor in patients with percutaneous coronary intervention after 12 months [J]. The Journal of Practical Medicine, 2021, 37(22): 2903-2907.
[11]	PANG Zhiying, YANG Fei, SU Yaying, LIU Feng, TANG Linmeng, CUI Shujun.. Impact of coronary CT angiography and CT⁃FFR on major adverse cardiac events in patients with obstructive coronary heart disease [J]. The Journal of Practical Medicine, 2021, 37(20): 2675-2680.
[12]	MA Chun⁃peng, LIU Xiaoli, CAI Lili, ZHU Aihong, DONG Xuefei, MA Chunming, MA Lixiang, WANG Qingsheng, NIE Shaoping . HEART risk score in chest pain patients with coronary heart disease in emergency department [J]. The Journal of Practical Medicine, 2021, 37(2): 215-219.
[13]	SONG Fenghua, ZHENG Yingying, TANG Junnan, GUO Qianqian, ZHANG Jianchao, CHENG Mengdie, JIANG Lizhu, WANG Kai, LIU Zhiyu, BAI Yan, ZHANG Jinying.. Association of mean platelet volume to lymphocyte ratio with long ⁃ term mortality after PCI in coronary heart disease：a cohort study [J]. The Journal of Practical Medicine, 2020, 36(24): 3353-3357.
[14]	ZHANG Ziping, FANG Guang, GUO Xiucai. Role of nicorandil in treatment of coronary heart disease based on Chinese Coronary Heart Disease Medi⁃cation Guidelines [J]. The Journal of Practical Medicine, 2020, 36(22): 3033-3037.
[15]	HUANG Jinghe, CHEN Simin, XU Yan, LENG Lili , CHEN Borong. The relationship between QRS ⁃ T angle and coronary artery disease and its predictive value for MACE [J]. The Journal of Practical Medicine, 2020, 36(22): 3130-3134.

Research progress on sodium⁃glucose cotransporter 2 inhibitors for in⁃stent restenosis after percutaneous coronary intervention

RichHTML

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References 56

Related Articles 15

Recommended Articles

Metrics

Comments